title: Reduction of acute and reactivated colitis in rats by an inhibitor of neutrophil activation.
abstract: Neutrophils have been implicated as major contributors to tissue injury in inflammatory bowel disease. In this study, we have assessed the effects of an inhibitor of neutrophil activation and adherence, NPC-18915 (4-¿2-[2-(2-benzofuranyl)phenyl]-(E)-ethenyl¿benzoic acid sodium salt), in models of both acute and reactivated colitis. Acute colitis was induced by intracolonic administration of a hapten. In other rats, colitis was reactivated 6 wk after a bout of acute colitis by subcutaneous administration of the hapten. NPC-18915 given during the first 4 days after induction of acute colitis significantly reduced tissue injury and the incidence of diarrhea and adhesions. When treatment of NPC-18915 was initiated after colitis was firmly established (48 h posthapten), it did not produce a significant effect. NPC-18915 was effective at significantly reducing colonic injury and granulocyte infiltration in the reactivated colitis model, and a similar effect could be observed in rats treated with antineutrophil serum. These results demonstrate that an inhibitor of neutrophil activation is effective in both acute and reactivated colitis, although in the former case, effectiveness is only seen when the drug is given before full establishment of colitis. These results also suggest that neutrophils, are a critical effector cell of hapten-induced colitis in the rat, particularly in the case of reactivated colitis.
authors.affiliation: Intestinal Disease Research Unit, University of Calgary, Alberta, Canada.
authors.forename: J L
authors.initials: JL
authors.lastname: Wallace
authors.forename: W
authors.initials: W
authors.lastname: McKnight
authors.forename: S
authors.initials: S
authors.lastname: Asfaha
authors.forename: D Y
authors.initials: DY
authors.lastname: Liu
mesh_terms: D000208:Acute Disease; D000818:Animals; D001565:Benzoates / Q000627:therapeutic use*; D001572:Benzofurans / Q000627:therapeutic use*; D003092:Colitis / Q000188:drug therapy* / Q000503:physiopathology / Q000628:therapy; D003106:Colon / Q000098:blood supply; D005290:Ferric Compounds / Q000097:blood / Q000493:pharmacokinetics; D007116:Immunization, Passive; D007958:Leukocyte Count / Q000187:drug effects; D007975:Leukotriene B4 / Q000096:biosynthesis; D008297:Male; D009504:Neutrophils / Q000187:drug effects* / Q000276:immunology / Q000502:physiology; D051381:Rats; D017208:Rats, Wistar; D012008:Recurrence; D012039:Regional Blood Flow / Q000187:drug effects
chemical_list: D001565:Benzoates; D001572:Benzofurans; D005290:Ferric Compounds; D007975:Leukotriene B4; C112691:NPC 18915